Drug News June 8, 2026
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
This article from Eli Lilly Press Releases covers: Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials.
Source: Eli Lilly Press Releases • Editorial summary by GLP-1 Price Guide
What This Means for You
This article from Eli Lilly Press Releases covers: Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials.
This article from Eli Lilly Press Releases covers: Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials.
Source: Eli Lilly Press Releases
Original source
Read the full article at Eli Lilly Press Releases